Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico.
Biomedical Research Unit of the Mexican Social Security Institute, Durango, Durango, Mexico; and Research Group on Diabetes and Chronic Illnesses, Durango, Durango, Mexico.
Adv Chronic Kidney Dis. 2018 May;25(3):261-266. doi: 10.1053/j.ackd.2018.02.011.
The objective of the study was to evaluate the efficacy of oral magnesium supplementation in the improvement of metabolic syndrome (MetS) and its components. This is a randomized double-blind, placebo-controlled clinical trial that enrolled 198 individuals with MetS and hypomagnesemia who were randomly allocated to receive either 30 mL of magnesium chloride 5% solution, equivalent to 382 mg of elemental magnesium (n = 100), or placebo solution (n = 98), daily for 16 weeks. Serum magnesium levels <1.8 mg/dL defined hypomagnesemia. At final conditions, a total of 48 (48%) and 76 (77.5%) individuals had MetS in the magnesium and placebo groups (P = 0.01), respectively. At baseline, percent of individuals with 3, 4, and 5 criteria of MetS in the magnesium group were 60.0%, 37.0%, and 3.0%, respectively, and in the control group 55.1%, 35.7%, and 9.2%, respectively. Between basal and final conditions, changes in the components of MetS were significantly higher in the magnesium than placebo groups: -3.6 ± 3.3 mmHg, P = 0.001 for systolic blood pressure; -5.5 ± 1.7 mmHg, P = 0.005 for diastolic blood pressure; -12.4 ± 3.6 mg/dL, P < 0.005 for fasting glucose; -61.2 ± 24 mg/dL, P = 0.003 for triglycerides; and 0.9 ± 0.4 mg/dL, P = 0.06 for high-density lipoprotein cholesterol. Magnesium supplementation improves MetS by reducing blood pressure, hyperglycemia, and hypertriglyceridemia.
本研究旨在评估口服镁补充剂在改善代谢综合征（MetS）及其组成部分方面的疗效。这是一项随机、双盲、安慰剂对照的临床试验，共纳入 198 名伴有低镁血症的 MetS 患者，将其随机分为两组，分别接受 30ml 5%氯化镁溶液（相当于 382mg 元素镁）（n=100）或安慰剂溶液（n=98），每日一次，持续 16 周。血清镁水平<1.8mg/dL 定义为低镁血症。在最终条件下，镁组和安慰剂组分别有 48（48%）和 76（77.5%）名患者患有 MetS（P=0.01）。基线时，镁组有 3、4 和 5 项 MetS 标准的患者比例分别为 60.0%、37.0%和 3.0%，而对照组分别为 55.1%、35.7%和 9.2%。在基线和最终条件之间，镁组代谢综合征各组成部分的变化明显高于安慰剂组：收缩压下降 3.6±3.3mmHg，P=0.001；舒张压下降 5.5±1.7mmHg，P=0.005；空腹血糖下降 12.4±3.6mg/dL，P<0.005；甘油三酯下降 61.2±24mg/dL，P=0.003；高密度脂蛋白胆固醇升高 0.9±0.4mg/dL，P=0.06。镁补充剂通过降低血压、高血糖和高三酰甘油血症来改善 MetS。
